Introduction
============

*Streptococcus suis* (*S. suis*) causes serious disease symptoms. It is one of the most important pathogens, and it is responsible for pneumonia, arthritis, septicemia, and meningitis in pigs and humans ([@B3]). So far, some researchers have reported that *S. suis* is able to form biofilms ([@B24]; [@B3]; [@B7]). Biofilm structures are packaged along with proteins, nucleic acids, extracellular polysaccharides (EPS), and other materials. Microbial cells within biofilm structures are tolerant to the host immune system, heat treatment, and antibiotics ([@B16]).

In accordance with the antigenicity of the capsule, the *S. suis* serotypes are determined. capsular polysaccharide synthesis (CPS) genes are located at the cps locus. Production of the capsule is encoded by CPS genes ([@B20]). Especially, previous studies have shown that the *S. suis* serotype 2 mutant impaired in capsule expression acquire a biofilm-positive phenotype ([@B22]). Moreover, a hydrophilic capsule may hinder hydrophobic structures or components important for biofilm formation by *S. suis* ([@B4]).

Azithromycin is an antibiotic useful for the treatment of bacterial infections. It is common knowledge that azithromycin is derived from erythromycin, belonging to macrolide. Recently, some reports have showed that subinhibitory concentrations of azithromycin decreases biofilm formation ([@B21]; [@B8]). Our laboratory recently reported that sub-minimal inhibitory concentrations (MICs) of tylosin and sub-MICs of erythromycin decreased biofilm formation of *S. suis* ATCC700794 ([@B27]; [@B23]). However, the relationship between azithromycin and biofilm formation by *S. suis* remains poorly understood. Therefore, the purpose of this study was to describe the use of proteomics to better understand the impact of azithromycin on *S. suis* biofilms *in vitro*. We found that azithromycin affected the CPS enzymes. Several cell surface proteins \[such as ATP-binding cassette (ABC) superfamily ATP-binding cassette transporter (G7SD52), CpsR (K0FG35), Cps1/2H (G8DTL7), CPS16F (E9NQ13), putative uncharacterized protein (G7SER0), NADP-dependent glyceraldehyde-3-phosphate dehydrogenase (G5L259), putative uncharacterized protein (G7S2D6), amino acid permease (B0M0G6), and NsuB (G5L351)\] were found to be implicated in biofilm formation. Especially, after growth with 1/2 MIC of azithromycin and 1/4 MIC of azithromycin, the capsular polysaccharide (CP) content of *S. suis* was significantly higher.

Materials and Methods {#s1}
=====================

Bacterial Strains and Growth Conditions
---------------------------------------

*Streptococcus suis* ATCC700794 was used in this study. Bacteria were grown aerobically at 37°C in Todd-Hewitt broth (THB; Summus Ltd, Harbin, Heilongjiang, China) or Todd-Hewitt broth agar (THA) supplemented with 5% (v/v) fetal bovine serum (Sijiqing Ltd, Hangzhou, Zhejiang, China). The cultures were used for the biofilm assays and the MIC assays.

Determination of Growth Inhibition Activity of Azithromycin
-----------------------------------------------------------

Minimal inhibitory concentration assays of azithromycin were done three times (refer to [@B25]), with a few modifications. Briefly, *S. suis* ATCC700794 was grown aerobically at 37°C in THB (Summus Ltd, Harbin, Heilongjiang, China) overnight. The overnight cultures were diluted in sterile physiological saline (corresponding to 1 × 10^8^ colony-forming units /ml). Then, dilute the cultures of *S. suis* ATCC700794 1:100 using sterile THB (Summus Ltd, Harbin, Heilongjiang, China). Finally, samples (100 μl) were added to the wells of a 96-well plate (Corning Costar^®^3599, Corning, NY, USA) containing serial dilutions of azithromycin in culture medium. Control bacteria were cultivated in the absence of azithromycin. The MIC was determined as the lowest concentration of azithromycin that completely inhibited *S. suis* growth after incubation for 24 h at 37°C.

The growth rates of *S. suis* ATCC700794 treated with 1/2 MIC of azithromycin and untreated *S. suis* ATCC700794 were analyzed (refer to [@B25]). Briefly, *S. suis* ATCC700794 treated without azithromycin and *S. suis* ATCC700794 treated with azithromycin (1/2 MIC) were incubated at 37°C for 12 h. Then, the samples were taken every hour for measuring OD 600 nm.

Biofilm Assay
-------------

Overnight cultures of *S. suis* were diluted in sterile THB supplemented with 5% (v/v) fetal bovine serum (corresponding to 1 × 10^8^ colony-forming units/ml). Then, the diluted overnight cultures (200 μl) was grown (24 h) in a 96-well plate (Corning Costar^®^ 3599, Corning, NY, USA) in the presence of 1/2 MIC, 1/4 MIC, 1/8 MIC, or 1/16 MIC of azithromycin. *S. suis* ATCC700794 treated without azithromycin was served as a control. Biofilms were treated as described by [@B25] with some modifications. Briefly, the medium, free-floating bacteria, and loosely bound biofilm were then removed by aspiration, and the wells were washed three times with sterile physiological saline. The remaining attached bacteria were fixed with 200 μl of 99% methanol (Guoyao Ltd, China) per well, and then the wells were left to dry. The wells were dyed for 30 min with 200 μl of 0.1% crystal violet (Sularbao Ltd, Beijing, China) per well. The stain was washed with water. Then, the dye was solubilized with 200 μl of 33% glacial acetic acid per well. Finally, the samples were measured the absorbance at 570 nm.

Scanning Electron Microscopy
----------------------------

The biofilm structure of *S. suis* was observed by scanning electron microscopy (refer to [@B25]). Briefly, overnight cultures of *S. suis* were diluted in sterile THB supplemented with 5% (v/v) fetal bovine serum (corresponding to 1 × 10^8^ colony-forming units/ml). Then, the diluted overnight cultures with 1/2 MIC of azithromycin or without azithromycin were added into wells of a six-well plate containing rough glass slide or glass slide. Free-floating bacteria and medium were removed after 24 h in culture. The biofilms were incubated overnight in fixation buffer, washed with cacodylate buffer and post-fixed for 90 min at room temperature in 1% (w/v) osmic acid containing 2 mM potassium ferrocyanide and 6% (w/v) sucrose in cacodylate buffer. Samples were dehydrated through a graded series of ethanol (50, 70, 95, and 100%), critical point dried, gold sputtered and examined using a scanning electron microscopy.

iTRAQ Analysis
--------------

Protein was extracted from *S. suis* cells at two different conditions (1/2 MIC of azithromycin-treated cells and non-treated cells). iTRAQ analysis was implemented at Shanghai Applied Protein Technology Co. Ltd (APT, Shanghai, China). Three biological replicates were evaluated to minimize the influence of less reliable quantitative information. iTRAQ analyses were performed as described by [@B27]. Briefly, protein digestion was performed according to the FASP procedure and the resulting peptide mixture was labeled using the 8-plex iTRAQ reagent. iTRAQ-labeled peptides were fractionated by strong cation exchange (SCX) chromatography using the AKTA Purifier system. LC--MS/MS analysis was performed on a Q Exactive mass spectrometer that was coupled to Easy nLC (Proxeon Biosystems, now Thermo Fisher Scientific).

Sequence Database Searching and Data Analysis
---------------------------------------------

Sequence database searching and data analysis were implemented at Shanghai Applied Protein Technology Co. Ltd (APT, Shanghai, China). Briefly, MS/MS spectra were searched using MASCOT engine embedded into Proteome Discoverer 1.3 against Uniprot database (133549 sequences, download at March 3, 2013) and the decoy database. For protein identification, the following options were used. Peptide mass tolerance = 20 ppm, MS/MS tolerance = 0.1 Da, enzyme = Trypsin, missed cleavage = 2, fixed modification: Carbamidomethyl (C), iTRAQ8plex(K), iTRAQ8plex (N-term), and variable modification:oxidation (M), FDR ≤ 0.01.

Quantitative RT-PCR Analysis
----------------------------

We investigated the effect of 1/2 MIC of azithromycin on the gene expression of CPS enzymes (CpsR, Cps1/2H, and CPS16F). *S. suis* was grown to mid-log phase and then the culture medium was supplemented with 1/2 MIC of azithromycin prior to further incubate at 37°C for 24 h. Control cells were incubated in the absence of azithromycin.

Quantitative RT-PCR were implemented as described by [@B25].

Briefly, bacteria were collected by centrifugation (10,000 × *g* for 5 min) and treated with an RNASE REMOVER I (Huayueyang Ltd, Beijing, China). Total RNA was extracted with a Bacterial RNA isolating kit (Omega, Beijing, China) according to the manufacturer's protocol. RNA was reverse transcribed using Maloney murine leukemia virus reverse transcriptase and random hexamers in a S1000^TM^ thermal cycler. Reverse transcription conditions were 90 min at 42°C and 15 min at 70°C. Real-time PCR was used for quantification of *cpsR, cps1/2H*, and *cps16F* mRNA expression. Relative copy numbers and expression ratios of selected genes were normalized to the expression of 16S rRNA gene (housekeeping gene). The 16S rRNA gene was used as an internal control for specific primers. The specific primers used for the quantitative RT-PCR were purchased from Takara and are listed in **Table [1](#T1){ref-type="table"}**. Triplicate reactions were prepared with 25 μl of PCR mixture containing 12.5 μl of IQ SYBR Green Supermix, 5 μl of cDNA, 1 μl of gene-specific primer, and 6.5 μl of RNase- and DNase-free water. The samples were amplified using a Bio-Rad MyCycler^TM^ thermal cycler (Bio-Rad Laboratories). The amplification conditions for *cpsR, cps1/2H, cps16F*, and16S rRNA were 94°C for 10 min followed by 40 cycles at 94°C for 15 s, 60°C for 60 s.

###### 

Primers used for the quantitative RT-PCR analysis.

  ------------------------------------------------------
  Genes        Primer sequence
  ------------ -----------------------------------------
  *cps1/2H*    Forward: 5′-GCCTCTTATTCAGGTTAT-3′\
               Reverse: 5′-GTTCTGCTACTGTTTCTC-3′

  *cps16F*     Forward: 5′-TGAACATAATGGAGCAAC-3′\
               Reverse: 5′-AGGACCAATCCGACAAGC-3′

  *cpsR*       Forward: 5′-TTCGGTAGTAGAAGGTTCAAGAC-3'\
               Reverse: 5′-AACACGCAAAGCTAAATAGGTAT-3′

  *16s rRNA*   Forward: 5′-GATATATGGAGGAACACCG-3′\
               Reverse: 5′-GACCCAACACCTAGCACT-3′
  ------------------------------------------------------

Quantitative Determination of CP
--------------------------------

*Streptococcus suis* ATCC700794 was treated with 1/2 MIC, 1/4 MIC or 1/8 MIC of azithromycin. *S. suis* ATCC700794 treated without azithromycin was served as a control. Isolation and purification of the CP from *S. suis* ATCC700794 were performed as described by Yufang et al. (refer to [@B26]). Briefly, a 10-ml overnight culture was used to inoculate 1L of THB containing 5% (v/v) fetal bovine serum for 24 h at 37°C. The bacterial cells were recovered by centrifugation and washed twice with PBS. The pellet was suspended in 100 ml of glycine buffer containing 100 mg lysozyme (Sigma). After incubation at 37^o^C for 8 h, the supernatant was recovered following centrifugation. The supernatant was treated with 20 mg of DNase (Sigma) and 10 mg of RNase (Sigma) at 37°C for 1 h. Proteinase K (20 mg) was added for 2 h at 55°C. The supernatant was brought to a concentration of 30% (v/v) ethanol and allowed to stand at 4°C for 2 h. The precipitate formed was removed by centrifugation, and the supernatant was brought to a concentration of 80% ethanol and allowed to stand at 4°C overnight. The precipitate was recovered by centrifugation and dried. Quantitative determination of the CP was performed as described by [@B5]. Briefly, the phenol solution (0.3 ml) and the CP solution (0.6 ml) were added to screw cap tubes, which were capped and vortex-stirred. Then 1.5 ml of concentrated sulfuric acid was added directly to the tube. The tubes were then closed, vortex-stirred for 5 s and incubated for 30 min. All samples were read the absorbances at 490 nm using distilled water as blank in a UV-7504 spectrophotometer (Jingke Ltd, Shanghai, China). Standard curve of glucose was performed as above described. The CP content was expressed according to the formula: CP content (%) = (*C* × *D* × *F/W*) × 100, where *C* is sugar concentration in the sample, *D* is dilution factor in the sample, *F* is conversion factor (3.19), and *W* is CP weight in the sample.

Statistical Analysis
--------------------

Assays were done three times and the means ± standard deviations were computed. Data were analyzed using the Student *t*-test.

Results
=======

Minimal inhibitory concentration of azithromycin against *S. suis* ATCC700794 was 32 μg/ml in the present study. Furthermore, after 10 h incubation at 37°C, untreated *S. suis* ATCC 700794 and treated (1/2 MIC of azithromycin) *S. suis* ATCC 700794 reached stationary phase, indicating no effect on growth rate of *S. suis* ATCC700794 (**Figure [1](#F1){ref-type="fig"}**). After growth without azithromycin (control) or with 1/2 MIC of azithromycin, 1/4 MIC of azithromycin, 1/8 MIC of azithromycin, or 1/16 MIC of azithromycin, biofilm formation of *S. suis* was investigated (**Figure [2](#F2){ref-type="fig"}**). When the culture medium was supplemented with 1/2 MIC of azithromycin, 1/4 MIC of azithromycin, or 1/8 MIC of azithromycin, the biofilms of *S. suis* were significantly lower in comparison with the control (*p* \< 0.05). However, after growth with 1/16 MIC of azithromycin, the biofilms were not significantly affected (*p* \> 0.05).

![**Growth curve of ATCC700794 in the absence of azithromycin and in the presence of 1/2 minimal inhibitory concentration (MIC) of azithromycin.** Data are expressed as means ± standard deviations.](fmicb-07-01659-g001){#F1}

![**Effect of sub-MICs of azithromycin on biofilm formation by *Streptococcus suis* ATCC700794.** Data are expressed as means ± standard deviations. Controls refer to the absence of azithromycin. Significantly different (^∗^*p* \< 0.05) compared to untreated control bacteria.](fmicb-07-01659-g002){#F2}

Scanning electron microscopy analysis was performed to observe the azithromycin sub-MIC-induced biofilm formation by *S. suis*. As shown in **Figures [3A,C](#F3){ref-type="fig"}** (control), a thick biofilm made of aggregates and microcolonies almost completely covered the surface of the glass slide. However, when the culture medium was supplemented with 1/2 MIC of azithromycin, individual short chains of *S. suis* and individual pairs of *S. suis* attached to the glass slide or rough glass slide (**Figures [3B,D](#F3){ref-type="fig"}**). Scanning electron microscopy analysis revealed that 1/2 MIC of azithromycin significantly decreased biofilm formation by *S. suis*.

![**Scanning electron micrographs of *S. suis* ATCC700794 biofilm following growth in THB supplemented without azithromycin \[**(A or C)**, control\], or with 1/2 MIC of azithromycin **(B or D)**.** Controls refer to the absence of azithromycin.](fmicb-07-01659-g003){#F3}

iTRAQ technology was used to compare the patterns of protein expression at two different conditions (1/2 MIC of azithromycin treated cells and non-treated cells). When a protein had both a fold-change of more that a ratio \>2.0 or \<0.5 (*p*-value \< 0.05), the protein was considered differentially expressed. On the basis of the two criteria, 19 differentially expressed proteins were identified, 12 (63.2%) of which displayed increased, and 7 (36.8%) displayed decreased abundance (**Table [2](#T2){ref-type="table"}**). According to the molecular function, these proteins were classified into following categories: nucleotide binding (4, 21.1%), DNA binding (1, 5.3%), catalytic activity (7, 36.8%), RNA binding (1, 5.3%), protein binding (1, 5.3%), structural molecule activity (1, 5.3%), transporter activity (1, 5.3%), motor activity (1, 5.3%), and unknown molecular function (9, 47.4%). According to the cellular component, these proteins were classified into following categories: membrane (9, 47.4%), cytoplasm (2, 10.5%), extracellular (1, 5.3%), cytoskeleton(1, 5.3%), and unknown cellular component (9, 47.4%). According to the biological process, these proteins were classified into following categories: metabolic process (5, 26.3%), cell organization and biogenesis (1, 5.3%), regulation of biological process (1, 5.3%), transport (2, 10.5%), cellular homeostasis (1, 5.3%), and unknown biological process (12, 63.2%). Detailed information can be found in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. The majority of the proteins were involved in catalytic activity (7, 36.8%) and metabolism (5, 26.3%). These findings suggested that 1/2 MIC of azithromycin-treated cells and non-treated cells were subjected to different pharmic selective pressures, which might result in different proteome patterns.

###### 

ITRAQ Identification of differentially expressed proteins.

  Accession                     Proteins                                                             Fold change^a^
  ----------------------------- -------------------------------------------------------------------- -------------------
  **Up-regulated proteins**                                                                          
  G5L351                        NsuB                                                                 7.12934739263001
  G5KZF5                        Putative uncharacterized protein                                     3.01653085375799
  G8DTL7                        Cps1/2H                                                              2.02407561418484
  G7SFA8                        Transcriptional regulator, Cro/CI family                             2.57596261219689
  G7S2D6                        Putative uncharacterized protein                                     3.00076898311981
  Q9EZW2                        Elongation factor Tu (Fragment)                                      3.9674279008791
  G7S4L6                        Putative uncharacterized protein                                     2.31735729535592
  B0M0G6                        Amino acid permease (Fragment)                                       2.16331972961307
  A4W361                        Uridine kinase                                                       7.48970780907174
  R4NZ92                        TPR repeat-containing protein                                        2.70348016201752
  G7SD52                        ABC superfamily ATP binding cassette transporter, membrane protein   5.6411425449412
  G7S7A9                        FAD-dependent pyridine nucleotide-disulfide oxidoreductase           2.96465802924635
  **Down-regulated proteins**                                                                        
  G7SER0                        Putative uncharacterized protein                                     0.206326492539119
  G7SHZ3                        Bacteriophage protein, putative                                      0.480729105006118
  K0FG35                        CpsR                                                                 0.369579660174813
  G5L259                        NADP-dependent glyceraldehyde-3-phosphate dehydrogenase, putative    0.374165986672724
  G7RZ18                        Sortase-like protein                                                 0.368308683014746
  E9NQ13                        CPS16F                                                               0.24025009068188
  G7SPA1                        Putative scaffolding protein                                         0.324624727229277

a

1/2 MIC azithromycin treated vs. non-treated cells.

When the culture medium was supplemented with 1/2 MIC of azithromycin, expression of the genes *cps1/2H* was upregulated (*p* \< 0.05; **Figure [4](#F4){ref-type="fig"}**). However, as shown in **Figure [4](#F4){ref-type="fig"}**, when the culture medium was supplemented with 1/2 MIC of azithromycin, expression of the genes *cpsR* and *cps16F* was downregulated (*p* \< 0.05). As shown in **Figure [5](#F5){ref-type="fig"}**, the CP content, in comparison with the control, was significantly higher (*p* \< 0.05) after growth with 1/2 MIC and 1/4 MIC of azithromycin. However, the CP content was not significantly affected following growth in the presence of 1/8 MIC of azithromycin (*p* \> 0.05).

![**Relative abundances of *cps1/2H, cps16F* and *cpsR* in 1/2 MIC azithromycin-treated and -untreated cell revealed by quantitative RT-PCR.** Data are expressed as means ± standard deviations. The expression was normalized to 16S rRNA. Controls refer to the absence of azithromycin. Significantly different (^∗^*p* \< 0.05) compared to untreated control bacteria.](fmicb-07-01659-g004){#F4}

![**Determination of capsular polysaccharide content of *S. suis* ATCC700794 using a phenol--sulfuric acid method.** Data are expressed as means ± standard deviations. Controls refer to the absence of azithromycin. Significantly different (^∗^*p* \< 0.05) compared to untreated control bacteria.](fmicb-07-01659-g005){#F5}

Discussion
==========

In the present study, the relationship between biofilm formation of *S. suis* and azithromycin have been investigated carefully. Some researchers have reported that subinhibitory concentrations of antimicrobial agents (such as moxifloxacin and triclosan) can either decrease ([@B17]) or increase ([@B1]) biofilm formation of bacterial pathogens. In the present study, we found that subinhibitory concentrations of azithromycin significantly decreased biofilm formation of *S. suis*. This finding is consistent with the previous publication ([@B21]; [@B8]).

Cell surface proteins and outer membrane proteins play a crucial role in biofilm formation of bacterial pathogens. Biofilm formation of bacterial pathogens mainly included three aspects: (i) bacterial pathogens adhere to surfaces, (ii) aggregation of micro-colonies of bacterial pathogens, and (iii) further expansion of the microbial community. Key stage of biofilm formation of bacterial pathogens is adhesion to surfaces. Cell surface proteins and outer membrane proteins may mediate cell attachment to surfaces.

When bacterial cells and a surface are close to each other, the biophysical interaction between a surface and bacterial cells plays an important role in adhesion. Therefore, cell surface proteins and outer membrane proteins play an important role in biofilm formation of bacterial pathogens. Membrane proteins such as OmpA mediate cell adhesion in *Acinetobacter baumannii* ([@B6]). In the present study, the expression of ABC superfamily ATP binding cassette transporter (G7SD52), CpsR (K0FG35), Cps1/2H (G8DTL7), CPS16F (E9NQ13), putative uncharacterized protein (G7SER0), NADP-dependent glyceraldehyde-3-phosphate dehydrogenase (G5L259), putative uncharacterized protein (G7S2D6), amino acid permease (B0M0G6), and NsuB (G5L351) changed; these proteins belong to membrane proteins and cell-surface proteins and might be involved in some molecular functions including transporter activity, nucleotide binding, motor activity, protein binding and catalytic activity (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). We predicted that these membrane proteins might affect the bacterial cell-cell interaction. Thus, membrane proteins might play a significant role in biofilm formation.

Interestingly, ABC superfamily ATP-binding cassette transporter (G7SD52) and NsuB (G5L351) was up-regulated in sub-MIC of azithromycin (in this study) and erythromycin-treated *S. suis* ([@B27]). However, molecular function and biological process of NsuB (G5L351) are currently unknown. In future, NsuB (G5L351) should be studied. CpsR (K0FG35) and CPS16F (E9NQ13) was down-regulated in sub-MIC of azithromycin (in this study) and erythromycin-treated *S. suis* ([@B27]). Especially, in the present study, azithromycin also affected the expression of the other proteins, for example, Putative uncharacterized protein (G7SER0), NADP-dependent glyceraldehyde-3-phosphate dehydrogenase (G5L259), putative uncharacterized protein (G7S2D6), and amino acid permease (B0M0G6). This finding is not consistent with the previous results of our laboratory showing that subinhibitory concentrations of erythromycin inhibit biofilm formation of *S. suis* ([@B27]). It is generally known that azithromycin is the same class antibiotics as erythromycin, belonging to macrolide. However, erythromycin did not affect the expression of the four proteins ([@B27]). In future, this finding should be studied carefully.

ABC transporters are common proteins in bacteria. They often transport a variety of substrates (for example polypeptides, ions and nutrients) ([@B15]). ABC transporters are also presumably involved in the export of the competence-stimulating peptide (autoinducers), which in turn regulate expression of specific target genes ([@B14]). Moreover, previous studies have also demonstrated that ABC transporters are important as they regulate biofilm formation ([@B19]). Shannon et al. have reported that ABC transporters are required for biofilm formation by *Pseudomonas fluorescens* WCS365 ([@B9]). Our laboratory recently reported that ABC superfamily ATP-binding cassette transporter (G7SD52) was up-regulated in sub-MIC of erythromycin or sub-MIC of tylosin-treated *S. suis* ([@B27]; [@B23]). In the present study, ABC superfamily ATP-binding cassette transporter (G7SD52) was upregulated in sub-MIC of azithromycin-treated cell (treated vs. untreated). However, azithromycin did not affect the expression of histidine kinase of the competence regulon (comD; G5L3D2) and response regulator (comE; G7S4A2) in the present study. Interestingly, erythromycin affects the expression of the two proteins ([@B27]). [@B14] have also found that comD and comE are implicated in biofilm formation of *S. mutans*. So far, the detailed molecular mechanism was still unknown.

Some researchers have reported that the *S. suis* mutant impaired in capsule expression acquire a biofilm-positive phenotype in the previous publication ([@B22]). Bonifait et al. have reported that a hydrophilic capsule hinder hydrophobic components or structures. Moreover, [@B4] have also found that the hydrophobic components or structures play an important role in biofilm formation of *S. suis*. Non-encapsulated *S. suis* strains may form thick biofilms ([@B2]). Specifically, in other species, [@B18] have reported that reduced *S. pneumoniae* CP may increase biofilm development. Joseph et al. reported that *Vibrio vulnificus* CP expression actually inhibited biofilm formation ([@B11]). [@B12] have reported that the inactivation of Cps2F (glycosyltransferases) often caused capsule loss in *S. suis*. Cps2F and Cps2H may be involved in the biosynthesis of serotype 2 CP. In this study, azithromycin affected the biosynthesis of the CPS enzymes, for example, CpsR (K0FG35), Cps1/2H (G8DTL7), and CPS16F (E9NQ13). This finding is consistent with the previous results of our laboratory showing that sub-MIC erythromycin inhibits biofilm formation of *S. suis* ([@B27]). However, Cps1/2H (G8DTL7) was downregulated (fold change: 0.30) in sub-MIC of erythromycin-treated *S. suis* ([@B27]). Interestingly, Cps1/2H (G8DTL7) was up-regulated (fold change: 2.024) in sub-MIC of azithromycin-treated *S. suis* (in this study). It is common knowledge that azithromycin is derived from erythromycin, belonging to macrolide. We speculated that azithromycin had different molecule structure in comparison with erythromycin, which in turn might generate the different proteome patterns. However, the detailed molecular mechanism was still unknown. In future, this finding should be studied carefully. In brief, we speculated that azithromycin might affect the biosynthesis of the CP.

Recently, Lee et al. have investigated the role of CP in biofilm formation in *V. vulnificus*. *V. vulnificus* mutant impaired in CP expression increases cell aggregation, adherence to abiotic surfaces, and hydrophobicity of the cell surface. In comparison with wild type, *V. vulnificus* mutant forms significantly more biofilm. Furthermore, addition of CP decrease biofilms formation of a CP-deficient mutant. After the CP-producing wild type is degraded endogenous CP with an enzyme, the CP-producing wild type increases biofilm formation ([@B13]). In the present study, the CP content, in comparison with the control, was significantly higher after growth with 1/2 MIC of azithromycin and 1/4 MIC of azithromycin. Houde et al. have reported that *S. suis* mutants impaired in capsule expression are easily killed by immune cells. Therefore, CP of *S. suis* is a significant virulence factor of the bacteria. Furthermore, CP is also involved in adhesion of the bacteria ([@B10]). Key stage of biofilm formation of bacterial pathogens is adhesion to surfaces. We speculated that azithromycin might affect adhesion of *S. suis* by increasing capsular polysaccharide content. In brief, further examination of the relationship of capsule structure to biofilms should be studied.

In short, subinhibitory concentrations of azithromycin might decrease biofilm formation of *S. suis* in the present study. At two different conditions (1/2 MIC of azithromycin non-treated cells and treated cells), we carried out comparative proteomic analyses of cells by using iTRAQ technology. In the present study, 19 differentially expressed proteins were identified, 12 (63.2%) of which displayed increased and 7 (36.8%) displayed decreased abundance. Several cell surface proteins \[such as ABC superfamily ATP-binding cassette transporter (G7SD52), CpsR (K0FG35), Cps1/2H (G8DTL7), CPS16F (E9NQ13), putative uncharacterized protein (G7SER0), NADP-dependent glyceraldehyde-3-phosphate dehydrogenase (G5L259), putative uncharacterized protein (G7S2D6), Amino acid permease (B0M0G6), and NsuB (G5L351)\] were found to be implicated in biofilm formation. It is common knowledge that azithromycin is derived from erythromycin, belonging to macrolide. We speculated that azithromycin had different molecule structure in comparison with erythromycin, which in turn might generate the different proteome patterns. We also discovered that azithromycin might affect the biosynthesis of the CP. These data showed a useful starting point for more focused studies to understand what exactly was going on. However, the detailed mechanism was still unknown. In future, the relationship between capsule structure and biofilms of *S. suis* should be studied to delineate the complex mechanism.
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